Supplemental material
Drug Delivery
Volume 24, 2017 - Issue 1
Open access
4,089
Views
15
CrossRef citations to date
0
Altmetric
Review Article
“Fusion and binding inhibition” key target for HIV-1 treatment and pre-exposure prophylaxis: targets, drug delivery and nanotechnology approaches
Tanushree Malik1 DBT Lab, Indo Soviet Friendship College of Pharmacy, Moga, India and
, Gaurav Chauhan1 DBT Lab, Indo Soviet Friendship College of Pharmacy, Moga, India and ;2 Centre for Nanosciences, Department of Chemical Engineering, Indian Institute of Technology Kanpur, Kanpur, India
, Goutam Rath1 DBT Lab, Indo Soviet Friendship College of Pharmacy, Moga, India and
, R. S. R. Murthy1 DBT Lab, Indo Soviet Friendship College of Pharmacy, Moga, India and
& Amit K. Goyal1 DBT Lab, Indo Soviet Friendship College of Pharmacy, Moga, India and Correspondence[email protected]
Pages 608-621
|
Received 10 Jul 2016, Accepted 22 Aug 2016, Published online: 26 Feb 2017
Related Research Data
Resistance to HIV Infection
Source:
Springer Science and Business Media LLC
HIV entry inhibitors: mechanisms of action and resistance pathways
Source:
Oxford University Press (OUP)
Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates
Source:
Mary Ann Liebert Inc
Liposomes for HIV prophylaxis
Source:
Elsevier BV
CD4 Binding Site Antibodies Inhibit Human Immunodeficiency Virus gp120 Envelope Glycoprotein Interaction with CCR5
Source:
American Society for Microbiology
Protein/peptide-based anti-HIV therapies
Source:
Wiley
A duodenally absorbable CXC chemokine receptor 4 antagonist, KRH-1636, exhibits a potent and selective anti-HIV-1 activity.
Source:
Proceedings of the National Academy of Sciences
Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region
Source:
Proceedings of the National Academy of Sciences
In situ stabilized AgNPs and (Cu-Cur)CD dispersed gel, a topical contraceptive antiretroviral (ARV) microbicide
Source:
Royal Society of Chemistry (RSC)
Dendrimer Delivery of Oligonucleotides
Source:
Informa UK Limited
The Anti-HIV Potency of Cyclotriazadisulfonamide Analogs Is Directly Correlated with Their Ability to Down-Modulate the CD4 Receptor
Source:
American Society for Pharmacology & Experimental Therapeutics (ASPET)
Griffithsin, a potent HIV entry inhibitor, is an excellent candidate for anti‐HIV microbicide
Source:
Wiley
Mutational pathways, resistance profile, and side effects of cyanovirin relative to human immunodeficiency virus type 1 strains with N-glycan deletions in their gp120 envelopes
Source:
American Society for Microbiology
Nanotechnology in vaccine delivery.
Source:
Elsevier BV
(Copper-curcumin) β-cyclodextrin vaginal gel: delivering a novel metal-herbal approach for the development of topical contraception prophylaxis.
Source:
Elsevier BV
Inhibiting HIV-1 Entry: Discovery of D-Peptide Inhibitors that Target the gp41 Coiled-Coil Pocket
Source:
Elsevier BV
Albumin stabilized silver nanoparticles–clotrimazole β-cyclodextrin hybrid nanocomposite for enriched anti-fungal activity in normal and drug resistant Candida cells
Source:
Royal Society of Chemistry (RSC)
Nanoparticle-based vaginal drug delivery systems for HIV prevention.
Source:
Informa Healthcare
Preparation and characterization of solid lipid nanoparticles containing silibinin.
Source:
Informa UK Limited
HIV-1 virion fusion assay: uncoating not required and no effect of Nef on fusion.
Source:
Elsevier Inc.
Core structure of GP41 from the HIV envelope glycoprotein
Source:
Elsevier BV
Lipid composition has significant effect on targeted drug delivery properties of NGR-modified liposomes.
Source:
Informa UK Limited
Structural basis for membrane fusion by enveloped viruses
Source:
Informa UK Limited
The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone.
Source:
American Society of Hematology
Rational Design of Targeted Next-Generation Carriers for Drug and Vaccine Delivery
Source:
Annual Reviews
Cationic liposomes are possible drug-delivery systems for HIV fusion inhibitor sifuvirtide
Source:
Royal Society of Chemistry (RSC)
A novel and efficient asymmetric synthesis of anti-HIV drug maraviroc
Source:
Informa UK Limited
CADA inhibits human immunodeficiency virus and human herpesvirus 7 replication by down-modulation of the cellular CD4 receptor.
Source:
Elsevier BV
Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults
Source:
Oxford University Press (OUP)
Atomic structure of the ectodomain from HIV-1 gp41
Source:
Springer Science and Business Media LLC
2008 Recommendations of the International AIDS Society–USA Panel
Source:
American Medical Association (AMA)
A Small Molecule CXCR4 Inhibitor that Blocks T Cell Line–tropic HIV-1 Infection
Source:
Rockefeller University Press
Epigallocatechin gallate, the main polyphenol in green tea, binds to the T-cell receptor, CD4: Potential for HIV-1 therapy.
Source:
Elsevier BV
cocktail therapeutic strategy for antiviral therapy
Source:
Ovid Technologies (Wolters Kluwer Health)
Protein design of an HIV-1 entry inhibitor
Source:
American Association for the Advancement of Science (AAAS)
Multiple Antiviral Activities of Cyanovirin-N: Blocking of Human Immunodeficiency Virus Type 1 gp120 Interaction with CD4 and Coreceptor and Inhibition of Diverse Enveloped Viruses
Source:
American Society for Microbiology
Evaluation of -2 RANTES Vaginal Microbicide Formulations in a Nonhuman Primate Simian/Human Immunodeficiency Virus (SHIV) Challenge Model
Source:
Mary Ann Liebert Inc
Capture of an early fusion-active conformation of HIV-1 gp41
Source:
Springer Science and Business Media LLC
In-vitro anti-viral screening and cytotoxicity evaluation of copper-curcumin complex.
Source:
Informa UK Limited
Resistance to enfuvirtide, the first HIV fusion inhibitor
Source:
Oxford University Press (OUP)
Initial Events in Establishing Vaginal Entry and Infection by Human Immunodeficiency Virus Type-1
Source:
Elsevier BV
Spirodiketopiperazine-Based CCR5 Inhibitor Which Preserves CC-Chemokine/CCR5 Interactions and Exerts Potent Activity against R5 Human Immunodeficiency Virus Type 1 In Vitro
Source:
American Society for Microbiology
Gold nanoparticles capped with sulfate-ended ligands as anti-HIV agents.
Source:
Elsevier BV
Simulations reveal that the HIV-1 gp120-CD4 complex dissociates via complex pathways and is a potential target of the polyamidoamine (PAMAM) dendrimer
Source:
AIP Publishing
Nanoparticulate drug carriers for delivery of HIV/AIDS therapy to viral reservoir sites
Source:
Informa Healthcare
Detection of functional galactosylceramide (GalCer) receptors on CD4-negative HIV-1 target cells
Source:
Springer Science and Business Media LLC
Nef Does Not Affect the Efficiency of Human Immunodeficiency Virus Type 1 Fusion with Target Cells
Source:
American Society for Microbiology
Vaginal microbicides and their delivery platforms.
Source:
Informa Healthcare
Dendrimers as potential therapeutic tools in HIV inhibition.
Source:
MDPI AG
Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion.
Source:
Rockefeller University Press
Development of Dual-Acting Pyrimidinediones as Novel and Highly Potent Topical Anti-HIV Microbicides
Source:
American Society for Microbiology
Development and characterization of niosomal gel for topical delivery of benzoyl peroxide
Source:
Informa UK Limited
Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1.
Source:
Springer Science and Business Media LLC
Molecular architecture of native HIV-1 gp120 trimers.
Source:
Springer Science and Business Media LLC
Microbicides and other topical agents in the prevention of HIV and sexually transmitted infections
Source:
Informa UK Limited
Interaction of silver nanoparticles with HIV-1
Source:
Springer Science and Business Media LLC
HIV-1 entry inhibitors: recent development and clinical use.
Source:
Elsevier BV
pH-sensitive nanoparticles: an effective means to improve the oral delivery of HIV-1 protease inhibitors in dogs.
Source:
Springer Science and Business Media LLC
Human Immunodeficiency Virus Type 1 Entry Inhibitors PRO 542 and T-20 Are Potently Synergistic in Blocking Virus-Cell and Cell-Cell Fusion
Source:
Oxford University Press (OUP)
Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target
Source:
Proceedings of the National Academy of Sciences
Nano-Systems for Advanced Therapeutics and Diagnosis of Atherosclerosis
Source:
Bentham Science Publishers Ltd.
A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding
Source:
Proceedings of the National Academy of Sciences
A trimeric structural domain of the HIV-1 transmembrane glycoprotein.
Source:
Springer Science and Business Media LLC
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.